Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Temferon
- Development stage
- Unknown
- Lead developer
- Genenta Science
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Temferon is an investigational, ex-vivo genetically modified cell therapy developed for cancer treatment, primarily glioblastoma multiforme (GBM). It is based on autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that are engineered using a lentiviral vector to express human interferon-alpha 2 (IFN-α2), under the control of the Tie2 promoter and post-transcriptional miRNA elements. After engraftment, these cells differentiate into Tie2-expressing monocytes/macrophages (TEMs), which home to tumors and locally release IFN-α within the tumor microenvironment. This targeted delivery aims to reprogram the tumor microenvironment by restoring immune function and counteracting tumor growth while minimizing systemic toxicity associated with IFN-α therapies. Temferon has received orphan drug designation from the FDA for GBM with unmethylated MGMT promoter status and is in Phase 1/2 clinical trials for this indication. Developers: Genenta Science
- Brand names
- Temferon
- Other names
- IFN-α2 modified CD34+ cells
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Temferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Temferon.